



Premature termination of a Clinical Trial

Full title of the clinical Trial:

Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis

EudraCT Number: 2007-005117-18

Sponsor: Medical University of Vienna, Department of Clinical Pharmacology

Represented by (name): Markus Zeitlinger, Assoc.Prof.Priv.Doiz.Dr.

Reason for premature termination of the clinical trial:

After a study period of two years and screening more than 150 patients only two patients of the planned 16/32 could be recruited in three clinical study sites in Vienna . Therefore, the completion of the study does not seem feasible in a reasonable period of time.

Study results (if available):

Because only two patients were recruited (one is a drop out) no further assessment of the results can be performed.

13. AUG. 2021

Date and Signature of Sponsor representative:



MEDIZINISCHE
UNIVERSITÄT WIEN

Universitätsklinik
für Klinische Pharmakologie
Währinger Gürtel 18-20, 1090 Wien
T: +43 (0)1 40400-29810
klin-pharmakologie@meduniwien.ac.at
www.meduniwien.ac.at/klpharm